|MDACC Study No:||2011-0448 (clinicaltrials.gov NCT No: NCT01286753)|
|Title:||An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine|
|Principal Investigator:||Maria E. Cabanillas|
|Study Description:||The goal of this clinical research study is to learn if vemurafenib can help to |
control papillary thyroid cancer. Researchers will also be studying the drug's
effect on biomarkers (proteins in the blood/tissue that may be related to your
reaction to the study drug). The safety and possible side effects of this drug
will also be studied.
Vemurafenib is designed to block the BRAF gene mutation. This mutation causes
cancer and cancer growth. By blocking this mutation, the drug may kill the
cancer cells with the mutation and/or stop the tumor from growing.